Immunocore Bolsters Board and Strikes Deal with BBA Funds
Company Announcements

Immunocore Bolsters Board and Strikes Deal with BBA Funds

Immunocore Holdings (IMCR) has provided an update.

Immunocore Holdings plc appointed Mr. Ranjeev Krishana, a seasoned executive with a history at Baker Bros. Advisors and Pfizer, to its Board of Directors on May 28, 2024. Krishana brings extensive pharmaceutical and international market experience to the role and will serve until the 2025 annual shareholder meeting. Concurrent with his appointment, the company entered into a Registration Rights Agreement with the BBA Funds, granting them rights for resale registration of certain company securities. This agreement entails the company’s commitment to file necessary registration statements upon request and allows the BBA Funds limited opportunities for underwritten offerings to sell their shares, with the company covering related expenses and providing indemnification.

Learn more about IMCR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmunocore reports Q3 EPS 17c, consensus (35c)
TheFlyImmunocore reports cash, equivalents of $901.3M as of September 30
TheFlyImmunocore initiated with a Sell at UBS
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App